Home >Current Issue

Volume: 9, Issue: 2, February, 2019
DOI: 10.7324/JAPS.2019.90213



Research Article

A post-market quality assessment of first-line, fixed-dose combination antiretrovirals in South Africa

Kim Ward, Reem Suleiman, Yunus Kippie, Admire Dube

  Author Affiliations


Abstract

South Africa has the world’s largest antiretroviral (ARV) program and despite having stringent upstream medicine’s regulatory oversight, the post-market reassessment of ARV quality is prohibitively resource intensive. The aim of this study was to evaluate and compare the post-market quality of four fixed-dose combination (FDC) generics containing efavirenz (EFV) 600 mg, emtricitabine 200 mg, and tenofovir 300 mg against the innovator, Atripla® and according to the International Pharmacopoeia (IP). Generic tablet samples, sourced from a South African provincial depot, were subjected to the identification, content assay, dissolution, uniformity of weight and disintegration tests. An in-house reversed-phase high-performance liquid chromatography (RP-HPLC) method was developed and validated in lieu of the RP-HPLC IP method which proved to be unsuitable. All samples passed the identification, assay, uniformity of weight and disintegration tests and one generic FDC failed the dissolution test (at both stage 1 and 2), releasing 62.23% (standard deviation 20.43) of EFV in 30 minutes. One generic first-line ARV combination that is currently supplied to the South African public health sector was found to be substandard and this reinforces the need for routine ARV post-market surveillance, as well as reliable compendial methods to facilitate this undertaking.

Keywords:

Quality control, antiretrovirals, dissolution, HPLC, fixed-dose combination, post-marketing surveillance.



Citation: Kim Ward, Reem Suleiman, Yunus Kippie, Admire Dube. A post-market quality assessment of first-line, fixed dose combination antiretrovirals in South Africa. J Appl Pharm Sci, 2019; 9(02):097–104.


Copyright: The Author(s). This is an open access article distributed under the Creative Commons Attribution Non-Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

Al Ameri, M.N., Nayuni, N., Kumar, K.G,A., Perret, D., Tucker, A. and Johnston, A. The differences between the branded and generic medicines using solid dosage forms: In-vitro dissolution testing. Results in Pharma Sciences 2012; 1-8.https://doi.org/10.1016/j.rinphs.2011.12.001 https://doi.org/10.1016/j.rinphs.2011.12.001

Al-Tamimi, S.K., Hassali, M.A. and Alrasheedy, A.Challenges to generic medicines utilization in Yemeni healthcare system.GaBi Journal. 2013;2.DOI: 10.5639/gabij.2013.0202.017 https://doi.org/10.5639/gabij.2013.0202.017

Aulton, M. and Taylor, K. eds. Aulton's Pharmaceutics, 5th Edition.The Design and Manufacture of Medicines. New York: Elsevier, 2017

Chien, C. HIV/AIDS drugs for Sub-Saharan Africa: How do brand and generic supply compare? Plos One 2007; 2(3): e278. doi.org/10.1371/journal.pone.0000278 https://doi.org/10.1371/journal.pone.0000278

Department of Health (DOH), South Africa. National Policy on HIV Pre-exposure Prophylaxis (PrEP) and Test and Treat (T&T). Government Printer: South Africa, 2016. http://www.sahivsoc.org/Files/PREP%20and%20TT%20Policy%20-%20Final%20Draft%20-%205%20May%202016%20(HIV%20news).pdf (Accessed 8 August 2018)

Department of Health (DOH).The South African antiretroviral treatment guideline.Version 14, 2013.http://www.kznhealth.gov.za/medicine/2013_art_guidelines.pdf (Accessed 4 March 2018).

Djobet, M.P., Singhe, D., Lohoue, J., Kuaban, C., Ngogang, J., and Tambo, E. Antiretroviral therapy supply chain quality control and assurance in improving people living with HIV therapeutic outcomes in Cameroon. AIDS Research and Therapy 2017; 14:19. doi.org/10.1186/s12981-017-0147-x https://doi.org/10.1186/s12981-017-0147-x

European Medicines Agency (EMEA). Atripla®: EPAR - scientific discussion, 2007. https://www.ema.europa.eu/documents/scientific-discussion/atripla-epar-scientific-discussion_en.pdf (Accessed 5 March 2017)

International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. Validation of analytical procedures: text and methodology Q2 (R1). International Conference on Harmonisation, Harmonised Tripartite Guideline, 2005

Genazzani, A. andPattarino, F. Difficulties in production of identical products from a pharmaceutical technology viewpoint. Drugs R D 2008; 9(2):65-72. http://dx.doi.org/10.2165/00126839-200809020-00001 https://doi.org/10.2165/00126839-200809020-00001

Joshi, A., Esseku, F., Silva, L., Igwilo, C., Oqua, D., Kunle, B., Obodozie, O., Inyang, U. andAdeyeye, M.C. Postmarketing in vitro/in vivo assessment of fixed dose combination products of first line antiretrovirals. Journal of Pharmaceutical Sciences 2010; 99(6): 2655–2663. https://www.ncbi.nlm.nih.gov/pubmed/20054854 (Accessed 6 April 2017)

Lehmann, A., Hofsäss, M. and Dressman, J. Differences in drug quality between South Africa and Germany.Journal of Pharmacy and Pharmacology 2018.DOI: 10.1111/jphp.12985 https://doi.org/10.1111/jphp.12985

Newton, P.N., Fernández, F.M., Green, M.D., Primo-Carpenter J. and White N.J.Counterfeit and Substandard Anti-infectives in Developing Countries. In: Sosa A., Byarugaba D., Amábile-Cuevas C., Hsueh PR., Kariuki S., Okeke I. (eds) Antimicrobial Resistance in Developing Countries. Springer, New York, 2010.http://emerald.tufts.edu/med/apua/about_us/publications_21_3125925763.pdf(Accessed 3 November 2017) https://doi.org/10.1007/978-0-387-89370-9_24

Maigetter, K., Pollock, A.M., Kadam, A., Ward, K. and Weiss, M.G. Pharmacovigilance in India, Uganda and South Africa with reference to WHO's minimum requirements. International Journal of Health Policy and Management 2015; 4(5): 295–305. DOI: 10.15171/IJHPM.2015.55 https://doi.org/10.15171/ijhpm.2015.55

NkansahP.,Smine K, Pribluda V, Phanouvong S, Dunn C, Walfish S, Umaru F, Clark A, Kaddu G, Hajjou M, and Nwokike J, Evans L. Guidance for Implementing Risk-Based Post-Marketing Quality Surveillance in Low- and Middle-Income Countries.U.S. Pharmacopeial Convention.The Promoting the Quality of Medicines Program. Rockville, Maryland, 2017.

Patel, A., Gauld, R., Norris, P. and Rades, T. Quality of generic medicines in South Africa: perceptions versus reality - a qualitative study. BioMed Central Health Services Research 2012; 12(1): 297. DOI: 10.1186/1472-6963-12-297 https://doi.org/10.1186/1472-6963-12-297

Primo-Carpenter J and McGinnis M. Matrix of drug quality reports in USAID-assisted countries by the US Pharmacopeia drug quality and information program, 2008.https://pdf.usaid.gov/pdf_docs/Pnadl275.pdf (Accessed 25 September 2018)

Raju, N.A. and Begum, S. Simultaneous RP-HPLC method for the estimation of Emtricitabine, Tenofovir disoproxilfumerate and Efavirenz in tablet dosage forms.Research Journal of Pharmacy and Technology 2008; 1(4): 522–525.

Raju, N.A., Rao, J.V., Prakash, K.V., Mukkanti, K. and Srinivasu, K. Simultaneous estimation of Tenofovir disoproxil, Emtricitabine and Efavirenz in tablet dosage form by RP-HPLC. Oriental Journal of Chemistry 2008; 24(2): 645–650.

Ramaswamy A andDhas ASAG.Development and validation of analytical method for quantitation of Emtricitabine, Tenofovir, Efavirenz based on HPLC.Arabian Journal of Chemistry 2014; 11(2): 275-281.https://doi.org/10.1016/j.arabjc.2014.08.007 https://doi.org/10.1016/j.arabjc.2014.08.007

Sharrad, A.K., Hassali, M.A. andShafie, A.A. Generic medicines perceptions of physicians in Basrah, Iraq.Austr.Med. J. 2009; 1:58–64.https://core.ac.uk/download/pdf/27270684.pdf (Accessed 13 August 2018)

United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS update 2016. Geneva, Switzerland, 2016.

United Nations Programme on HIV/AIDS (UNAIDS). Together we will end AIDS. Geneva, Switzerland, 2012.

World Health Organization (WHO). Fixed-dose combinations for HIV/AIDS, tuberculosis, and malaria - report of a meeting held 16-18 December 2003 Geneva, 2003. http://apps.who.int/iris/handle/10665/68967 (Accessed 7 February 2017)

World Health Organization (WHO).International Pharmacopoeia (IP) - sixth edition. 2016. Monographs: Dosage forms: Specific monographs: Efavirenz, emtricitabine and tenofovir tablets (Efavirenzi, emtricitabiniettenofoviricompressi) Geneva, Switzerland, 2016a.

World Health Organization (WHO).International Pharmacopoeia (IP) - sixth edition. 2016. Methods of analysis: Pharmaceutical technical procedures: Uniformity of mass for single-dose preparations 2016. Geneva, Switzerland, 2016b.

World Health Organization (WHO).International Pharmacopoeia (IP) - sixth edition. 2016. Methods of analysis: Pharmaceutical technical procedures: Disintegration test for tablets and capsules Geneva, Switzerland, 2016c.

World Health Organization (WHO).Survey of the quality of antiretroviral medicines circulating in selected African countries. Geneva, Switzerland, 2007.

World Health Organisation (WHO).WHO Global surveillance and monitoring system for substandard and falsified medical products. Geneva: World Health Organisation, 2017.https://www.who.int/medicines/regulation/ssffc/publications/gsms-report-sf/en/ (Accessed 5 August 2018)

Article Metrics

Similar Articles

Development and validation of dissolution procedures
Bhavesh Vaghela, Rajan Kayastha, Nayana Bhatt, Nimish Pathak and Dashrath Rathod

An unlimited scope for novel formulations as orally disintegrating systems: Present and future prospects
Reeta Rani Thakur , Mridul Kashi

A validated stability indicating HPLC method for the determination of Valsartan in tablet dosage forms
Della Grace Thomas Parambi,Molly Mathew and V.Ganesan